Forest Hopeful No More Trials Needed For Milnacipran Fibromyalgia Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
Priority review could bring the drug to market in June, at the same time competitor Lilly’s Cymbalta may be approved for the indication.
You may also be interested in...
Forest Boosts 2009 R&D Spend 27%; FY 2008 Revenues Up 11%
Late-stage pipeline investment could bring billions in ten years, CEO Olanoff says.
Forest Boosts 2009 R&D Spend 27%; FY 2008 Revenues Up 11%
Late-stage pipeline investment could bring billions in ten years, CEO Olanoff says.
Milnacipran Standard Review Sets Up Launch After Cymbalta In Fibromyalgia
Cypress Biosciences tells the DAILY it is optimistic about potential differentiation for fibromyalgia candidate, even if milnacipran will be the third drug to market for the condition.